TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10749622
Drug: Any cytokine
Normalized name: cytosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any cytokine treatment
Study: 9361572
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous heparin for 10 days
Study: 9361572
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous heparin for 5 days
Study: 9361572
Drug: Pooled analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pooled analysis of continuous intravenous heparin
Study: 4037710
Drug: Primperan (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primperan (30 mg per day for 15 days)
Study: 29189318
Drug: NANCAL-guided remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: NANCAL-guided remifentanil administration
Study: 29189318
Drug: Fixed remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed remifentanil concentration at 4 ng/ml
Study: 26449721
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg amphetamine
Study: 26449721
Drug: d-amphetamine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (various doses) in mice
Study: 18203890
Drug: EGG group
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGG group (intake of 3 eggs per day, 640 mg/d additional dietary cholesterol)
Study: 16434933
Drug: At least
Normalized name: Lovaza 1000 MG (at least 900 MG) Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: At least one neuroleptic treatment change (44.9% in public, 39.2% in private)
Study: 12588387
Drug: Calcitriol 3
Normalized name: CALCITRIOL 3MCG/GM OINT,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol 3 microg g(-1) ointment
Study: 12588387
Drug: Calcipotriol 50
Normalized name: Calcipotriol 50 microgram/g cutaneous cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol 50 microg g(-1) ointment
Study: 10735152
Drug: Novel iso-osmotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel iso-osmotic laxative
Study: 8671231
Drug: Simplified ultralong
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simplified ultralong protocol (ULP) of gonadotrophin-releasing hormone agonist (GnRHa) with a single injection of 3.75 mg Decapeptyl followed by daily s.c. administration of 0.1 mg Decapeptyl for at least 2 weeks prior to ovarian stimulation.
Study: 8671231
Drug: Long protocol
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long protocol (LP) of gonadotrophin-releasing hormone agonist (GnRHa) with daily s.c. administration of 0.1 mg Decapeptyl initiated from the mid-luteal phase of the preceding cycle.
Study: 6431075
Drug: Metered 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered 0.4 mg nitroglycerin spray
Study: 6431075
Drug: Soft gelatin
Normalized name: Norvir Soft Gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft gelatin capsule containing 0.8 mg nitroglycerin solution
Study: 6431075
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin tablet
Study: 31706331
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri DSM 17938 (1 × 10^8 CFU, 5 drops once daily)
Study: 15669595
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (rhGH) at 0.025 IU/kg/day for 1 week, increasing to 0.05 IU/kg/day for 8 weeks
Study: 15669595
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (rhGH) with normal CRP levels
Study: 10516940
Drug: Psiquial (fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psiquial (fluoxetine formulation)
Study: 10516940
Drug: Prozac (fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prozac (fluoxetine formulation)
Study: 7864430
Drug: Preoperative enalaprilat
Normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative enalaprilat (1.25 mg intravenously [i.v.] 20 min prior to induction)
Study: 7864430
Drug: Intraoperative enalaprilat
Normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative enalaprilat (0.625 mg i.v. at the onset of tourniquet‐associated hypertension)
Study: 27002298
Drug: Trabodenoson 500
Normalized name: Trabodenoson
DrugBank: Trabodenoson (DB13122)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabodenoson 500 mcg
Study: 17241298
Drug: PAC7 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAC7 group (omeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg twice daily for 7 days)
Study: 11986086
Drug: Cidofovir 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cidofovir 1% four times daily
Study: 11986086
Drug: Cidofovir 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cidofovir 1% ten times daily
Study: 11986086
Drug: Cidofovir 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cidofovir 1% four times daily and Cyclosporin A 1% four times daily
Study: 11986086
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride four times daily
Study: 7625773
Drug: Glycerol administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol administration (20 g) alone
Study: 7625773
Drug: Glycerol administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol administration (20 g) with a mixed meal
Study: 7625773
Drug: Glycerol administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol administration (20 g)
Study: 30947531
Drug: sustained-release bupropion
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sustained-release bupropion (switch)
Study: 30947531
Drug: sustained-release bupropion
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sustained-release bupropion (combination)
Study: 30947531
Drug: aripiprazole (augmentation)
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: aripiprazole (augmentation)
Study: 28114909
Drug: High intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intensity treatment (HIT) composed of low glycemic index diet + exercise + vitamin D (60ng/mL serum concentration)
Study: 28114909
Drug: Lower intensity
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower intensity treatment (LITE) with general advice to follow a healthy diet and exercise pattern + vitamin D to avoid insufficiency
Study: 25451240
Drug: GABA-ergic neurotransmission
Approvals — FDA: no, EMA: no, PMDA: no
Description: GABA-ergic neurotransmission via alprazolam (GABAA receptor agonist)
Study: 20413036
Drug: hANP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hANP infusion (0.02 microg/kg/min)
Study: 17953462
Drug: OGT oral
Normalized name: OGT-2378
DrugBank: Sinbaglustat (DB17619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OGT oral spray taken five times daily
Study: 15590244
Drug: Multisensory therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multisensory therapy (n = 36 sessions for 12 weeks)
Study: 15590244
Drug: Activity therapy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activity therapy (n = 36 sessions for 12 weeks)
Study: 12395981
Drug: FDC tablet
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC tablet containing rifampicin, isoniazid, pyrazinamide, and ethambutol
Study: 12395981
Drug: Separate formulations
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate formulations of rifampicin, isoniazid, and pyrazinamide
Study: 10395837
Drug: Zanamivir 2x
Normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanamivir 2x daily for 5 days
Study: 10395837
Drug: Zanamivir 4x
Normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanamivir 4x daily for 5 days
Study: 2115407
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous recombinant tissue-type plasminogen activator (rt-PA) (0.75 mg/kg over 1 hour)
Study: 2115407
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous rt-PA (0.75 mg/kg over 1 hour; total dose, 100 mg over 6 hours)
Study: 2115407
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (low-dose rt-PA, high-dose rt-PA, placebo)
Study: 6111212
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 or 200 mg)
Study: 20852079
Drug: Dietary florfenicol
Normalized name: Florfenicol
DrugBank: Florfenicol (DB11413)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary florfenicol (0.02 g/kg; 16 wk)
Study: 20852079
Drug: Sequential use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential use of florfenicol (0.02 g/kg; 8 wk) and DVAQUA (0.5 g/kg; 8 wk)
Study: 20852079
Drug: Dietary DVAQUA
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary DVAQUA (0.5 g/kg; 16 wk)
Study: 16381264
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion at 0.04 microg/kg/min
Study: 16381264
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion starting at 2 mg/kg/h reduced to 1 mg/kg/h
Study: 8904056
Drug: Aspirin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (80 mg daily)
Study: 26655421
Drug: Ibrutinib (420
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib (420 mg daily orally) with bendamustine plus rituximab
Study: 22992073
Drug: BG-12 (dimethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: BG-12 (dimethyl fumarate) 240 mg twice daily
Study: 22992073
Drug: BG-12 (dimethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: BG-12 (dimethyl fumarate) 240 mg three times daily
Study: 19240689
Drug: NV1FGF plasmid
Normalized name: plasmin
DrugBank: Fibrinolysin (DB05254)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NV1FGF plasmid DNA (0.5, 2, or 4 mg administered as eight IM injections)
Study: 10022444
Drug: Human BNP
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human BNP infusion (3.0 pmol/kg min)
Study: 10022444
Drug: NEP inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEP inhibitor (SCH 42495, 300 mg)
Study: 10022444
Drug: Combined BNP
Normalized name: BNP
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined BNP and NEP inhibitor
Study: 2081639
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated lyophilized Schwartz strain of measles vaccine
Study: 7002178
Drug: Tofizopam 100
Normalized name: tofisopam
DrugBank: Tofisopam (DB08811)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Tofizopam 100 mg
Study: 29970053
Drug: Iron-folic acid
Normalized name: folic acid / iron carbonyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-folic acid supplements provided by trained BRAC village volunteers during early pregnancy
Study: 27378790
Drug: Levosimendan (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (0.1 μg/kg/min for 24 h without a loading dose)
Study: 12728461
Drug: 5 ppm
Normalized name: silver nitrate 55 PPM TOPICAL GEL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ppm NO via inhalation followed by a recruitment maneuver (RM) with sustained inflation pressure of 30‐35 cmH2O for 30 seconds (Group 1)
Study: 12728461
Drug: NO inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO inhalation alone (Group 3)
Study: 10383502
Drug: OAC regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC regimen (omeprazole 20 mg b.d., amoxycillin 500 mg t.d.s., clarithromycin 200 mg b.d.)
Study: 10383502
Drug: LAC regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAC regimen (lansoprazole 30 mg b.d., amoxycillin 500 mg t.d.s., clarithromycin 200 mg b.d.)
Study: 10383502
Drug: RAC regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAC regimen (rabeprazole 20 mg b.d., amoxycillin 500 mg t.d.s., clarithromycin 200 mg b.d.)
Study: 8848769
Drug: Pasteur vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasteur vaccine (5 micrograms at 0, 1, 2, 6, 18 months)
Study: 8848769
Drug: Recombinant vaccine
Normalized name: CHO Cells Recombinant Vaccine
DrugBank: CHO Cells Recombinant Vaccine (DB15893)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant vaccine (40 micrograms at 0, 1, 2, 6, 12 months)
Study: 8848769
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional doses
Study: 8848769
Drug: Monitoring and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monitoring and administration of additional doses
Study: 1906584
Drug: Insulin alone
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin alone (n = 22)
Study: 1906584
Drug: Combined insulin-glibenclamide
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined insulin-glibenclamide therapy (n = 25)
Study: 6341191
Drug: Urol medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urol medication
Study: 6341191
Drug: Spasmoanalgetic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spasmoanalgetic therapy
Study: 28426542
Drug: Inhalation aromatherapy
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation aromatherapy (3-minute inhalation before chemotherapy cycles)
Study: 17393787
Drug: Control (routine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (routine treatment only)
Study: 15848554
Drug: Enteric-coated mycophenolate
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteric-coated mycophenolate sodium (EC-MPS; 720 mg bid)
Study: 15848554
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF; 1000 mg bid)
Study: 7616802
Drug: Heparin (1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (1250 IU twice a day subcutaneously for 30 days)
Study: 7616802
Drug: Prednisone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (10 mg per day for 30 days)
Study: 28089764
Drug: Tailored online
Normalized name: FILTER,SUCTION,INLINE #FHBF200S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored online coaching with EHR tracking tools (CC)
Study: 16879301
Drug: MBP8298 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBP8298 (500 mg administered intravenously every 6 months)
Study: 31793731
Drug: S. alopecuroides
Approvals — FDA: no, EMA: no, PMDA: no
Description: S. alopecuroides extract (400 mg capsules, once daily)
Study: 27614318
Drug: Lubricin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubricin (150 μg/mL) eye drops
Study: 24746942
Drug: Beclometasone/formoterol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclometasone/formoterol (200 μg/24 μg for children; 400 μg/24 μg for adolescents and adults) via pMDI with AeroChamber Plus™
Study: 24746942
Drug: Beclometasone/formoterol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclometasone/formoterol (400 μg/24 μg) via pMDI with AeroChamber Plus™
Study: 23688206
Drug: Acoustic Wave
Normalized name: aconite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acoustic Wave Therapy (AWT(®)), treated once a week for 7 weeks, total of 8 treatments
Study: 20074465
Drug: 1 percent
Normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin 0.1 Percent]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 percent chlorhexidine gel (TG)
Study: 15120931
Drug: Iseganan 9mg
Normalized name: Iseganan
DrugBank: Iseganan (DB16010)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iseganan 9mg oral rinse, swished/swallowed six times daily for up to 21 days.
Study: 15120931
Drug: Placebo oral
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral rinse, swished/swallowed six times daily for up to 21 days.
Study: 9783307
Drug: rHuEpo subcutaneously,
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEpo subcutaneously, 900 U/kg week‐1, 3 times weekly, supplemented with iron and vitamin E
Study: 25113527
Drug: Efavirenz 600
Normalized name: efavirenz 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz 600 mg nightly for 7 days
Study: 25113527
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of a serotonin 2A receptor antagonist
Study: 21366472
Drug: Bolus administration
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus administration of furosemide every 12 hours
Study: 21366472
Drug: High-dose furosemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose furosemide (2.5 times previous oral dose)
Study: 21366472
Drug: Low-dose furosemide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose furosemide (equivalent to previous oral dose)
Study: 9347277
Drug: Propafenone (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (450 to 750 mg)
Study: 7504134
Drug: Doxazosin (10.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (10.3 ± 6.3 mg/day)
Study: 7504134
Drug: Hydrochlorothiazide (44.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (44.0 ± 11.0 mg/day)
Study: 30462162
Drug: Combined-exercise program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined-exercise program and nutrition supplement
Study: 29326030
Drug: ADT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADT plus abiraterone acetate (1000 mg) and prednisone (5 mg) once daily
Study: 24559816
Drug: Sedative music
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedative music intervention (soft, instrumental slow music, 60-80 beats per minute, 40 minutes duration, for 6 weeks)
Study: 20568023
Drug: Conivaptan 20
Normalized name: conivaptan 20 mg/100 mL-D5% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conivaptan 20 mg IV as a bolus followed by 20 mg IV over 24 h
Study: 12124866
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral prasterone
Study: 12124866
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg oral prasterone
Study: 10574618
Drug: IFN-beta1b (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-beta1b (8 million international units, subcutaneous)
Study: 10574618
Drug: IFN-beta1a (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-beta1a (6 million international units, intramuscular)
Study: 1827021
Drug: Isradipine (7.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (7.9 +/- 3.5 mg/day)
Study: 1827021
Drug: Atenolol (69.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (69.2 +/- 43.5 mg/day)
Study: 31757691
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injections (IAIs) 2 mg every 4 weeks for the first 6 months, followed by 2 mg every 8 weeks.
Study: 28255094
Drug: Face-to-face cognitive-behavioural
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face cognitive-behavioural therapy (CBT)
Study: 26729009
Drug: Concise cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concise cognitive behavioural therapy and/or pharmacotherapy
Study: 21637131
Drug: MFGM-enriched complementary
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFGM-enriched complementary food (40 g/day)
Study: 12505243
Drug: Experimental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment after disease progression or relapse
Study: 9860474
Drug: Adjuvant hepatic
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant hepatic arterial infusion (HAI) of 5-fluorouracil (5-FU) 1000 mg/m2 per day for 5 days plus folinic acid 200 mg/m2 per day for 5 days
Study: 9860474
Drug: Adjuvant hepatic
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant hepatic arterial infusion (HAI) of 5-FU
Study: 2375249
Drug: Tolfenamic acid
Normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolfenamic acid 200 mg
Study: 2375249
Drug: Tolfenamic acid
Normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolfenamic acid 400 mg
Study: 29611892
Drug: MLC901 (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLC901 (0.8 g capsules 3 times daily)
Study: 25272643
Drug: Stannous chloride
Normalized name: Stannous chloride
DrugBank: Stannous chloride (DB11056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stannous chloride dihydrate at concentrations of 200, 400, 600, and 800 microg, followed by intravenous administration of 99mTc at 30 min intervals in group one.
Study: 25272643
Drug: Constant concentration
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant concentration of 400 microg of Sn PYP, followed by administration of 99mTc at different time intervals (15, 30, 60, and 120 min) in group two.
Study: 18235411
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of thoracic irradiation and chemotherapy (platinum salts and etoposide)
Study: 7569587
Drug: HRT (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT (oral or non-oral 17-beta estradiol at skeletally protective dose)